emetine (ACER-2820) / National Institutes of Health, Zevra Therapeutics - LARVOL DELTA

Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling. (PubMed, Front Pharmacol) - "The identification of known Wnt inhibitors such as emetine, tyrphostin A9, niclosamide, ouabain, and podophyllotoxin further validated the assay's robustness. Collectively, this study establishes a robust 1536-well screening platform for identifying Wnt pathway modulators and identifies topotecan, amsacrine, brefeldin A, and tyrphostin AG 879 as candidate small-molecule antagonist, thereby expanding the chemical tools for investigating Wnt/β-catenin signaling."

Journal • CNS Disorders • Fibrosis • Immunology • Oncology

Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health (GlobeNewswire, Acer Therapeutics Inc.) - "Acer Therapeutics Inc....today announced it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS)...to develop emetine hydrochloride as a potential treatment for patients with COVID-19....Acer is working toward an IND submission in mid-2020 and targeting clinical trial initiation in the third quarter of 2020....The Company has proposed an adaptive design Phase 2/3 randomized, blinded, placebo-controlled multi-center trial.... Biomedical Advanced Research and Development Authority (BARDA) invited the Company to present the emetine development program at the BARDA CoronaWatch meeting on May 7, 2020."

IND • Licensing / partnership • New P2/3 trial • Infectious Disease • Novel Coronavirus Disease